Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: A randomized, double-blind, multicenter phase III trial

Clinical Therapeutics

Volumn 35, Issue 9, 2013, Pages

  Kim, Sang Hyun ^a,b   Kim, Min Kyung ^a,c   Seo, Hong Seok ^d   Hyun, Min Soo ^e   Han, Kyoo Rok ^f   Cho, Seong Wook ^g   Kim, Young Kwon ^h   Hoon Park, Seong ⁱ  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Seoul National University Hospital Healthcare System Gangnam Center   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e Soonchunhyang University   (South Korea)

^f Kangdong Sacred Heart Hospital   (South Korea)

^g Bundang Jesaeng Hospital   (South Korea)

^h Dongguk University Ilsan Hospital   (South Korea)

ⁱ Ewha Womans University School of Medicine   (South Korea)

Author keywords

Controlled release formulation; Dyslipidemia; Simvastatin; Simvastatin administration and dosage

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; EPICONDYLITIS; EVENING DOSAGE; FEMALE; GINGIVA HYPERPLASIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MORNING DOSAGE; MYALGIA; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; TABLET; THORAX PAIN; TRIACYLGLYCEROL BLOOD LEVEL;

CONTROLLED-RELEASE FORMULATION; DYSLIPIDEMIA; SIMVASTATIN; SIMVASTATIN ADMINISTRATION AND DOSAGE;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG CHRONOTHERAPY; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIMVASTATIN; TABLETS; TRIGLYCERIDES;

EID: 84884354947     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.06.020     Document Type: Article

References (25)

1. Pyorala K., Ballantyne C.M., Gumbiner B., et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: Subgroup analyses of the scandinavian simvastatin survival study (4s). Diabetes Care 2004, 27:1735-1740.
2. Pedersen T.R., Olsson A.G., Faergeman O., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the scandinavian simvastatin survival study (4s). 1998. Atheroscler Suppl 2004, 5:99-106.
3. Morales D., Chung N., Zhu J.R., et al. Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the goalls and statt studies. Curr Med Res Opin 2004, 20:1235-1243.
4. Mabuchi H., Kita T., Matsuzaki M., et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan lipid intervention trial (J-LIT). Circ J 2002, 66:1096-1100.
5. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
6. Perk J., De Backer G., Gohlke H., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012, 33:1635-1701.
7. Plakogiannis R., Cohen H. Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration. Ann Pharmacother 2007, 41:106-110.
8. Tharavanij T., Wongtanakarn S., Lerdvuthisopon N., et al. Lipid lowering efficacy between morning and evening simvastatin treatment: a randomized double-blind study. J Med Assoc Thai 2010, 93(Suppl 7):S109-S113.
9. Plakogiannis R., Cohen H., Taft D. Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia. Am J Health Syst Pharm 2005, 62:2491-2494.
10. Cilla D.D., Gibson D.M., Whitfield L.R., Sedman A.J. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol 1996, 36:604-609.
11. Martin P.D., Mitchell P.D., Schneck D.W. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol 2002, 54:472-477.
12. Tsai K.T., Chen J.H., Wen C.J., et al. Medication adherence among geriatric outpatients prescribed multiple medications. Am J Geriatr Pharmacother 2012, 10:61-68.
13. Williams B., Shaw A., Durrant R., et al. Patient perspectives on multiple medications versus combined pills: a qualitative study. QJM 2005, 98:885-893.
14. Munger M.A., Van Tassell B.W., LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. MedGenMed 2007, 9:58.
15. Cutler D.M., Everett W. Thinking outside the pillbox-medication adherence as a priority for health care reform. N Engl J Med 2010, 362:1553-1555.
16. Jang S.B., Lee Y.J., Lim L.A., et al. Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. Clin Ther 2010, 32:206-216.
17. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2000;284:3043-3045.
18. Sbarouni E., Flevari P., Kroupis C., et al. The effects of raloxifene and simvastatin on plasma lipids and endothelium. Cardiovasc Drugs Ther 2003, 17:319-323.
19. Lund T.M., Torsvik H., Falch D., et al. Effect of morning versus evening intake of simvastatin on the serum cholesterol level in patients with coronary artery disease. Am J Cardiol 2002, 90:784-786.
20. Saito Y., Yoshida S., Nakaya N., et al. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler Thromb 1991, 11:816-826.
21. Johnson M.L., Pietz K., Battleman D.S., Beyth R.J. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Am J Manage Care 2004, 10:926-932.
22. Greenberg R.N. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984, 6:592-599.
23. Murray M.D., Birt J.A., Manatunga A.K., Darnell J.C. Medication compliance in elderly outpatients using twice-daily dosing and unit-of-use packaging. Ann Pharmacother 1993, 27:616-621.
24. Hixson-Wallace J.A., Dotson J.B., Blakey S.A. Effect of regimen complexity on patient satisfaction and compliance with warfarin therapy. Clin Appl Thromb Hemost 2001, 7:33-37.
25. De Geest S., von Renteln-Kruse W., Steeman E., et al. Compliance issues with the geriatric population: complexity with aging. Nurs Clin N Am 1998, 33:467-480.